Core Insights - Jilin Changlong Pharmaceutical (08049) reported a revenue of 439 million RMB for the six months ending June 30, 2025, representing a year-on-year growth of 11.6% [1] - The profit attributable to shareholders was 103 million RMB, showing a slight decline of 1.2% compared to the previous year [1] - The basic earnings per share stood at 18.38 cents [1] Financial Performance - The gross margin for the period was approximately 82.4%, which is an increase compared to the period ending June 30, 2024 [1] - The board attributes the improved gross margin to a reduction in production and material costs [1]

Core Viewpoint - Jilin Changlong Pharmaceutical (08049) reported a revenue of 439 million RMB for the six months ending June 30, 2025, representing an 11.6% year-on-year increase, while the profit attributable to shareholders decreased by 1.2% to 103 million RMB [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 439 million RMB, up 11.6% compared to the same period last year [1] - Profit attributable to shareholders was 103 million RMB, reflecting a decline of 1.2% year-on-year [1] - Basic earnings per share were 18.38 cents [1] Margins and Costs - The gross margin for the period was approximately 82.4%, which is an increase compared to the period ending June 30, 2024 [1] - The board attributes the improved gross margin to a reduction in production and material costs [1]

2025 2025 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就因本報告全部或部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本報告（吉林省輝南長龍生化藥業股份有限公司的董事（「董事」）願共同及個別對此負全責）乃遵照 GEM證券上市規則（「GEM上市規則」）的規定而提供有關吉林省輝南長龍生化藥業股份有限公司 及其附屬公司（「本集團」）的資料。董事經作出一切合理查詢後，確認就彼等所知及所信：(1)本 報告所載資料在各重大方面均屬準確及完整，且無誤導成份；(2)並無遺漏任何事實致使本報告 所載任何聲明產生誤導；及(3)本報告內表 ...

Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 中期業績公告 截至二零二五年六月三十日止六個月 香 港 聯 合 交 易 所 有 限 公 司（「聯 交 所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小 型 公 司 提 供 一 個 上 市 的 市 場。有 意 投 資 者 應 了 解 投 資 於 該 等 公 司 的 潛 在 風 險， 並 應 經 過 審 慎 周 詳 的 考 慮 後 方 作 出 投 資 決 定。 由 於GEM上 市 公 司 一 般 為 中 小 型 公 司，在GEM買賣的證券可能會較於聯交所 主 板 買 賣 的 證 券 承 受 較 大 的 市 場 波 動 風 險，同 時 無 法 保 證 在GEM買賣的證券 會 有 高 流 通 量 的 市 場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 會 就 因 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 佈 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 董事會會議通告 吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司（「本公司」）之 董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 五 年 八 月 十 四 日（星 期 四）上 午 十 時 假 座 中 華 人 民 共 和 國（「中 國」）吉 林 省 通 化 市 輝 南 縣 朝 陽 鎮 經 濟 開 發 區 舉 行，以 便： 承董事會命 吉林省輝南長龍生化藥業股份有限公司 吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 主 席 張 弘 1. 考 慮 及 批 准 本 公 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 吉林省輝南長龍生化藥業股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08049 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 172,500,000 | RMB | | | 0.1 RMB | | 17,250,000 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 172,500,000 | RMB | | | 0.1 RMB | | 17,250,000 | | 2. ...

Financial Performance - The total revenue for the year ended December 31, 2024, was approximately RMB 881,157,000, an increase of 4.7% from RMB 841,545,000 in the previous year[18]. - Profit attributable to owners of the Company increased to RMB 184,250,000 from RMB 148,207,000, representing a growth of 24.3%[18]. - Basic earnings per share rose to RMB 32.89 cents, up from RMB 26.45 cents, marking an increase of 24.5%[18]. - For the year ended December 31, 2024, the Group's revenue increased from RMB 841,545,000 to RMB 881,157,000, representing a growth of approximately 4.7%[38]. - The profit attributable to owners of the Company for the year increased from RMB 148,207,000 to RMB 184,250,000, reflecting a growth of about 24.3%[38]. - Basic earnings per share rose from RMB 26.45 cents last year to RMB 32.89 cents, an increase of approximately 24.4%[38]. - The Group recorded a revenue of approximately RMB 881,157,000 for the year ended December 31, 2024, an increase of 4.4% from RMB 841,545,000 in the previous year[65]. - Profit before income tax for 2024 was RMB 207,160,000, up from RMB 198,314,000 in 2023, indicating a growth of 4.4%[138]. - The profit attributable to owners of the Company for the year was RMB 184,250,000, compared to RMB 148,207,000 in 2023, reflecting a significant increase of 24.3%[138]. Market Strategy and Operations - The Company focused on maintaining market share for its leading product, Hai Kun Shen Xi Jiao Nang, while exploring new markets[20]. - The management emphasized enhancing sales through academic collaborations and participation in national nephrology conferences to stabilize clinical sales[20]. - The Company successfully navigated challenges such as market downturns and policy adjustments, achieving the goals set at the beginning of the year[19]. - Strong leadership and timely decisions from management were highlighted as key factors in the Company's performance[19]. - The Company aims to leverage its competitive advantages for new achievements in the coming years[19]. - The focus on drug quality and market sales orientation was emphasized as a strategy for future development[19]. - The Company emphasized sales and distribution to ensure steady growth of dominant products, particularly in injectable varieties[66]. Research and Development - The Company reported 22 drugs passing the consistency evaluation, with 10 drugs receiving drug registration approvals and 3 new drugs signed during the year[23]. - The Company strengthened its new drug research and development efforts, collaborating with multiple domestic pharmaceutical universities and institutions[23]. - The Group invested approximately RMB 37,324,000 in research and development projects during the year[57]. - The Company deployed a microscopic inspection system in its R&D and testing center, laying the groundwork for the development of traditional Chinese medicine varieties[64]. - New extraction equipment was added in the Traditional Chinese Medicine Extraction Workshop II, expanding production capacity and range[58]. - Thioctic Acid Injection, Furosemide Injection, Urapidil Hydrochloride Injection, and Levocarnitine API obtained registration approvals and have been put into commercial production, enriching the Company's product portfolio[59]. Financial Management and Investments - The expected annualized rate of return for wealth management products subscribed during the year was around 2%–2.5%, compared to 2.5%–3.25% in 2023[39]. - The Company held Wealth Management Products totaling approximately RMB93,265,000, with unrealized gains on fair value change amounting to approximately RMB3,265,000[43][44][45][50]. - The expected annualized return rates for the Wealth Management Products ranged from 2.00% to 2.5%, with the total initial investments being RMB90,000,000[44]. - The Group's investment in time deposits as of December 31, 2024, amounted to approximately RMB1,258,656,000, an increase from RMB937,003,000 in 2023[50]. - The subscriptions of Wealth Management Products were aimed at maximizing the utilization of surplus cash while maintaining high liquidity and low risk, with no losses experienced on these products as of December 31, 2024[47][51]. - The management has shifted investment strategies towards time deposits due to a decrease in principal guaranteed Wealth Management Products and an increase in long-term time deposit returns[48][51]. - A Risk Management Committee has been established to enhance the assessment and management of investments in Wealth Management Products and time deposits[49][52]. - The gain realized from Wealth Management Products for the year ended December 31, 2024, was approximately RMB3,265,000, compared to RMB608,000 in 2023[50][52]. - The Company will continue to seek opportunities to invest idle cash in appropriate Wealth Management Products to enhance overall earnings in the long run[47][51]. - The total unrealized gains on fair value change from Wealth Management Products represented approximately 0.79% to 1.66% of the Group's total assets as of December 31, 2024[44]. - The management considers the subscriptions to Wealth Management Products to be fair and reasonable, benefiting the Group and its shareholders[47][51]. Corporate Governance and Structure - The Company does not recommend the payment of a final dividend for the year[126]. - The Group's principal activity remains the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC[123]. - There were no changes in the nature of the Group's principal activities during the year[123]. - The Group's revenue is entirely generated from sales in the PRC, with all identifiable assets located in the PRC[124]. - As of December 31, 2024, the company's distributable reserves amounted to approximately RMB 1,404,720,000, an increase from RMB 1,244,158,000 in 2023[148]. - The group sold about 9.92% of its goods to its five largest customers in the year, up from 5.5% in 2023, with the largest customer accounting for 2.99% of total sales[149]. - Purchases from the five largest suppliers accounted for approximately 31.6% of total purchases, an increase from 28% in 2023, with the largest supplier representing 9.54% of total purchases[149]. - The group had no future plans for material investments or significant changes in capital assets of subsidiaries and affiliated companies as of December 31, 2024[142]. - The group's operations were primarily financed by shareholders' equity, with a treasury policy of placing cash in interest-bearing deposits[145]. - The group did not employ any financial instruments for hedging purposes due to minimal foreign exchange exposure[158]. - There were no capital commitments or material contingent liabilities as of December 31, 2024[159][160]. - The directors and supervisors of the company have service contracts or letters of appointment for a term of three years[168]. - The group did not purchase, sell, or redeem any of its listed securities during the year[170]. - No directors had a significant beneficial interest in any contracts of significance to the business of the group during the year[169]. - The Company has no provisions for pre-emptive rights under its articles of association or PRC laws[190]. - The Audit Committee reviewed the financial reporting procedures and internal control systems of the Group[193]. - The Company did not grant any rights to acquire shares to directors, supervisors, or chief executives during the year[181]. - The summary of the Group's results and assets for the last five financial years is available on page 124 of the annual report[195]. - The Company has no competing interests from its directors or significant shareholders[189]. Employee and Corporate Culture - The company has a total of 745 employees, with remuneration based on market conditions and individual performance[82]. - The company is committed to enhancing corporate culture and employee welfare to boost morale and teamwork[31]. - The company is committed to maintaining high environmental and social standards to ensure sustainable development[86].

Company Overview - Jilin Province Huinan Changlong Bio-pharmacy Company Limited is listed on the GEM of the Stock Exchange with stock code 8049[19]. - The company has confirmed that the information in the annual report is accurate and complete in all material respects[10]. - The board of directors includes six executive directors and three independent non-executive directors[15][16]. - The principal banker for the company is the Industrial and Commercial Bank of China, Huinan County Branch[18]. - The company operates its principal place of business in Hong Kong at Room 1101–2, 11/F, Office Tower Two, Grand Plaza[18]. - The company’s legal address is located in Huinan County, Tonghua, Jilin Province, PRC[19]. - The company’s website is http://www.jlchanglong.com[20]. - The Company was established as a state-owned enterprise in 1989 and was converted into a joint stock limited company in 1996[125][132]. - The Company's H shares have been listed on the GEM of the Stock Exchange of Hong Kong Limited since 24 May 2001[126]. Financial Performance - The total revenue of the Group for the year ended 31 December 2024 was approximately RMB 881,157,000, an increase of 4.7% from RMB 841,545,000 in the previous year[22]. - Profit for the year attributable to owners of the Company increased to RMB 184,250,000, up 24.3% from RMB 148,207,000 last year[22]. - Basic earnings per share increased to RMB 32.89 cents from RMB 26.45 cents, representing a growth of 24.5%[22]. - For the year ended December 31, 2024, the Group's revenue increased from RMB841,545,000 to RMB881,157,000, representing a growth of approximately 4.7%[42]. - The profit attributable to owners of the Company for the year increased from RMB148,207,000 to RMB184,250,000, marking an increase of about 24.3%[42]. - Basic earnings per share rose from RMB26.45 cents to RMB32.89 cents, reflecting an increase of approximately 24.4%[42]. - The gross profit margin for the year ended December 31, 2024, was approximately 77.8%, reflecting an increase of 8.4% compared to 69.4% for the year ended December 31, 2023[79]. - Profit before income tax rose to RMB 207,160,000, a 4.4% increase from RMB 198,314,000 in 2023[142]. - Total assets grew to RMB 2,531,106,000, an increase of 9.1% from RMB 2,318,824,000 in 2023[143]. - Total liabilities increased to RMB 901,492,000, up 7.5% from RMB 838,444,000 in 2023[143]. - Net assets reached RMB 1,629,614,000, a 10.1% increase from RMB 1,480,380,000 in 2023[143]. Research and Development - The Group invested approximately RMB37,324,000 in research and development projects during the year[61]. - The Small Volume Injection Workshop II passed GMP compliance inspection and commenced operations, enhancing production capacity[62]. - New extraction equipment was added in the Traditional Chinese Medicine Extraction Workshop II, expanding production capacity and range[66]. - The Company obtained registration approvals for Thioctic Acid Injection, Furosemide Injection, Urapidil Hydrochloride Injection, and Levocarnitine API, which have been put into commercial production[63]. - The Company has strengthened its quality training programs in collaboration with industry experts to enhance the skills of its employees[29]. - The Group has intensified R&D investment by establishing a new R&D and testing center to enhance its R&D capabilities[78]. - The R&D team has been awarded two new patents, which are expected to strengthen the product portfolio and drive future sales growth[109]. Market Strategy and Growth - The Company is focused on expanding market sales through academic collaborations and participation in national nephrology conferences[24]. - The Company plans to continue exploring and adjusting business strategies, increasing investment in technology and product research and development[34]. - The Company aims to leverage government strategies for the healthcare industry to facilitate diversified development[30]. - The company is expanding its market presence, targeting Southeast Asia with plans to establish distribution channels by Q3 2024[106]. - A strategic acquisition of a smaller biotech firm is in progress, which is anticipated to enhance the company's R&D capabilities and add 50 million in annual revenue[107]. - The company has set a future outlook with a revenue target of 1.5 billion for the next fiscal year, indicating a projected growth rate of 25%[102]. - New product development includes the launch of two innovative pharmaceuticals, which are expected to contribute an additional 200 million in revenue over the next year[105]. - The company plans to increase its marketing budget by 30% to support the launch of new products and enhance brand visibility[110]. Governance and Compliance - The company is committed to compliance with the GEM listing rules and has established various committees including an audit committee and a remuneration committee[16][18]. - The Audit Committee reviewed the financial reporting procedures and internal control system, including the audited results for the year ended December 31, 2024[198]. - The Company acknowledges the importance of environmental, social, and corporate governance in enhancing shareholder value[36]. - The Directors do not recommend the payment of a final dividend for the year ended 31 December 2024[130][137]. - The Group has only one business segment, focusing on Chinese medicines and pharmaceutical products[128][135]. - The business review of the Group is included in the "Management Discussion and Analysis" section of the annual report[134]. Investment and Financial Management - As of December 31, 2024, the Group held Wealth Management Products totaling approximately RMB93,265,000, up from RMB90,608,000 in 2023[54]. - The unrealised gains on fair value change from the Wealth Management Products amounted to approximately RMB3,265,000 as of December 31, 2024[49]. - The expected annualised rate of return for the Wealth Management Products subscribed during the year was around 2%–2.5%, compared to 2.5%–3.25% in 2023[43]. - The Group's investment in time deposits amounted to approximately RMB1,258,656,000 as of December 31, 2024, an increase from RMB937,003,000 in 2023[54]. - The management has shifted investment strategy towards time deposits due to decreasing returns on Wealth Management Products and increasing returns on long-term time deposits[52]. - The Group did not experience any losses on the Wealth Management Products as of December 31, 2024, and the subscriptions were funded by surplus cash[51]. - A Risk Management Committee has been established to strengthen the assessment and management of investments in Wealth Management Products and time deposits[53]. Employee and Shareholder Information - The Group maintains a total of 745 employees, with remuneration based on market conditions and individual performance[86]. - As of December 31, 2024, Zhang Hong holds 101,937,000 Domestic Shares, representing 26.29% of Domestic Shares and 18.19% of total registered Share Capital[182]. - Huinan County SAB is a substantial shareholder with 81,975,000 Domestic Shares, accounting for 21.14% of Domestic Shares and 14.63% of total registered Share Capital[190]. - The interests of Directors, supervisors, and chief executives in shares were disclosed as of December 31, 2024, with no additional interests reported[183]. - None of the Directors or significant shareholders had interests in competing businesses[193].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 393,093,000, a decrease of 0.4% compared to RMB 395,636,000 for the same period in 2023[2] - Gross profit increased to RMB 315,079,000, representing a 18.4% increase from RMB 266,027,000 year-on-year[2] - Operating profit rose to RMB 127,806,000, up 19.4% from RMB 107,137,000 in the previous year[2] - Profit attributable to shareholders was RMB 104,282,000, a significant increase of 29.0% compared to RMB 80,848,000 in 2023[2] - Basic earnings per share increased to 18.61 cents, up from 14.43 cents in the same period last year[2] - The total revenue for the six months ended June 30, 2024, was RMB 423,209,000, representing an increase of 3% from RMB 410,726,000 in the same period of 2023[9] - Pharmaceutical sales decreased slightly to RMB 393,093,000 from RMB 395,636,000, indicating a decline of approximately 0.6% year-over-year[9] - Other income significantly increased to RMB 30,116,000, up from RMB 15,090,000, marking a growth of 99.5%[9] - Operating profit for the period was impacted by depreciation costs of RMB 10,902,000, down from RMB 32,675,000 in the previous year, reflecting a decrease of 66.6%[9] - The income tax expense for the six months was RMB 22,711,000, a decrease from RMB 24,500,000, which is a reduction of 7.3%[10] - Basic earnings per share increased to RMB 104,282,000, compared to RMB 80,848,000 in the same period last year, representing a growth of 29.0%[10] Assets and Liabilities - Total non-current assets amounted to RMB 1,202,021,000, an increase from RMB 1,117,683,000 as of December 31, 2023[4] - Current assets totaled RMB 1,162,802,000, a decrease from RMB 1,201,141,000 at the end of 2023[5] - Total liabilities decreased to RMB 666,941,000 from RMB 725,289,000 at the end of 2023[5] - Net assets increased to RMB 1,584,662,000, compared to RMB 1,480,380,000 at the end of 2023[5] - Inventory as of June 30, 2024, was valued at RMB 82,356,000, down from RMB 102,972,000, indicating a decrease of 20.0%[13] - The carrying value of property, plant, and equipment decreased to RMB 251,904,000 from RMB 261,559,000, reflecting a decline of 3.7%[11] - The company maintained a cash and bank balance of approximately RMB 342,221,000 as of June 30, 2024, with a net asset value of approximately RMB 1,584,662,000[21] - As of June 30, 2024, the company had short-term bank borrowings of RMB 80,000,000, resulting in a debt-to-equity ratio of approximately 5.05%[22] - The company’s trade receivables as of June 30, 2024, amounted to RMB 273,590,000, compared to RMB 268,327,000 as of December 31, 2023[14] Shareholder Information - As of June 30, 2024, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[25] - The major shareholder, Huinan County Caiyuan Investment Co., Ltd., holds 81,975,000 shares, accounting for 21.14% of domestic shares and 14.63% of total registered capital[27] Corporate Governance - The audit committee consists of three independent non-executive directors, responsible for overseeing financial procedures and internal control systems[31] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[29] - The board of directors has not fully complied with the corporate governance code regarding the separation of the roles of chairman and CEO[30] - There are no known interests held by directors or major shareholders in businesses that may compete with the group[28] Operational Developments - The company expanded its production capacity with the commissioning of new facilities for small-volume injections and added new extraction equipment for traditional Chinese medicine[20] - The company successfully registered several products, including Eberprostat tablets and Dexamethasone sodium phosphate injection, which have entered commercial production[20] - The company is committed to developing potential business opportunities to drive growth and achieve better results in the future[25] - The company employed 678 staff as of June 30, 2024, down from 928 staff a year earlier[32] - The company did not repurchase, sell, or redeem any of its listed shares during the six-month period ending June 30, 2024[33]

吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 中期業績公告 截至二零二四年六月三十日止六個月 香 港 聯 合 交 易 所 有 限 公 司（「聯 交 所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小 型 公 司 提 供 一 個 上 市 的 市 場。有 意 投 資 者 應 了 解 投 資 於 該 等 公 司 的 潛 在 風 險， 並 應 經 過 審 慎 周 詳 的 考 慮 後 方 作 出 投 資 決 定。 由 於GEM上 市 公 司 一 般 為 中 小 型 公 司，在GEM買賣的證券可能會較於聯交所 主 板 買 賣 的 證 券 承 受 較 大 的 市 場 波 動 風 險，同 時 無 法 保 證 在GEM買賣的證券 會 有 高 流 通 量 的 市 場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 ...